In this episode of the 2 Minute Medicine Podcast: Pharma Roundup, we explore how innovation, regulation, and global strategy are reshaping the pharmaceutical landscape. We begin with the FDA’s approval of Enbumyst, the first intranasal loop diuretic for edema, offering patients with heart, kidney, or liver disease a faster and more convenient alternative to oral or intravenous therapy. Next, we turn to the FDA’s sweeping crackdown on misleading drug advertisements, marking a dramatic shift after years of lax enforcement and signaling a renewed emphasis on patient safety and transparency. We then spotlight Samsung BioLogics’ $1.3 billion U.S. contract, a deal that underscores how pharmaceutical manufacturing is adapting to tariff pressures and the need for secure biologics supply chains. Finally, we close with new data showing how Wegovy not only promotes weight loss but also reduces “food noise” and enhances mental well-being for patients, reframing obesity as both a metabolic and psychological condition. Together, these stories highlight how drug delivery, regulation, global production, and mental health insights are converging to define the next era of pharmaceutical care.